Theravance Biopharma, Inc.
General ticker "TBPH" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $553.3M (TTM average)
Theravance Biopharma, Inc. follows the US Stock Market performance with the rate: 52.5%.
Estimated limits based on current volatility of 1.3%: low 16.52$, high 16.95$
Factors to consider:
- Total employees count: 97 (-2.0%) as of 2024
- US accounted for 100.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Lack of profitability, Declining product acceptance, Regulatory and compliance, Labor/talent shortage/retention, Partnership obligations
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [14.40$, 25.70$]
- 2026-12-31 to 2027-12-31 estimated range: [13.93$, 24.97$]
Financial Metrics affecting the TBPH estimates:
- Negative: with PPE of -124.1 at the end of fiscal year the price was high
- Negative: negative Operating income
- Positive: Operating cash flow per share per price, % of 25.47 > 12.96
- Positive: Return on assets ratio (scaled to [-100,100]) of 17.90 > 6.12
- Positive: -14.24 < Investing cash flow per share per price, % of -11.24
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: 42.60 < Shareholder equity ratio, % of 61.11 <= 64.25
- Positive: Interest expense per share per price, % of 0.26 <= 0.73
- Positive: Inventory ratio change, % of 0 <= 0
Short-term TBPH quotes
Long-term TBPH plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $57.42MM | $64.38MM | $107.46MM |
| Operating Expenses | $113.46MM | $111.33MM | $120.71MM |
| Operating Income | $-56.03MM | $-46.95MM | $-13.25MM |
| Non-Operating Income | $6.77MM | $2.33MM | $142.49MM |
| Interest Expense | $2.35MM | $2.55MM | $2.46MM |
| R&D Expense | $40.62MM | $37.64MM | $37.41MM |
| Income(Loss) | $-49.27MM | $-44.61MM | $129.25MM |
| Taxes | $5.92MM | $11.80MM | $23.35MM |
| Profit(Loss)* | $-55.19MM | $-56.42MM | $105.89MM |
| Stockholders Equity | $213.00MM | $175.54MM | $296.72MM |
| Assets | $382.00MM | $354.16MM | $485.57MM |
| Operating Cash Flow | $-27.00MM | $-11.54MM | $238.54MM |
| Capital expenditure | $2.49MM | $0.33MM | $0.04MM |
| Investing Cash Flow | $-32.70MM | $12.28MM | $-105.28MM |
| Financing Cash Flow | $-198.93MM | $-2.50MM | $-3.25MM |
| Earnings Per Share** | $-1.00 | $-1.15 | $2.10 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.